MoFo BioMeter - A quarterly deal report covering the biotechnology industry
Posted: January 2, 2013
By: Morrison & Foerster
BioMeter takes the pulse of the industry by looking at a key measure of deal value—upfront payments—for deals in all stages of development. In our first report, we analyze more than 1,000 biotechnology transactions between 2006 and 2011 and the first three quarters of 2012. The numbers show the average upfront payment in licensing, collaboration, and development agreements was $35.5 million for all stages of development from 2006 through 2011. The numbers also show that figure moved significantly higher in 2011 and the first quarter of 2012 as the biotech market shifted toward transactions for approved products.
Share this content with your network.
By clicking this 'Download Now' box, you consent to BioCentury forwarding your information
to the company that wrote this White Paper and you agree that said company can use